Search

Your search keyword '"Sterman, Daniel H."' showing total 537 results

Search Constraints

Start Over You searched for: Author "Sterman, Daniel H." Remove constraint Author: "Sterman, Daniel H."
537 results on '"Sterman, Daniel H."'

Search Results

3. Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma

4. Pleural fluid microbiota as a biomarker for malignancy and prognosis

5. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma

6. Asbestosis

7. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome

8. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype

10. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

13. IMPACTS ON MANAGEMENT OF HIGH-RISK LUNG NODULES AND PATIENT OUTCOMES AFTER VIRTUAL REVIEW BY A MULTIDISCIPLINARY LUNG NODULE REVIEW BOARD

17. Clinical Outcomes in Critically Ill Coronavirus Disease 2019 Patients: A Unique New York City Public Hospital Experience

18. Supplementary File Table All (excel) from Lower Airway Dysbiosis Affects Lung Cancer Progression

19. Supplementary Table from Lower Airway Dysbiosis Affects Lung Cancer Progression

20. Supplementary Figure All from Lower Airway Dysbiosis Affects Lung Cancer Progression

21. Data from Lower Airway Dysbiosis Affects Lung Cancer Progression

22. Supplementary Figure Legends from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

23. Supplementary Methods from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

24. Supplemental Tables from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

25. Supplementary Table 1 from A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

26. Supplementary Figure 2 from A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

27. Supplementary Figure 1 from A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

28. Supplementary Figure 3 from A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

29. Supplementary Figures from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

42. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk

43. sj-pdf-1-aop-10.1177_10600280211028882 – Supplemental material for Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk

48. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial

Catalog

Books, media, physical & digital resources